Rapid Micro Biosystems (NASDAQ: RPID) issues preliminary 2025 revenue and Q4 business update

Rhea-AI Filing Summary

Rapid Micro Biosystems, Inc. reported that it has released a press release with preliminary, unaudited revenue results and selected business highlights for the fourth quarter and full year ended December 31, 2025. The update is being shared through a furnished Form 8-K, which means the revenue information and commentary are provided for investors but are not deemed filed for liability purposes under certain Exchange Act provisions. The press release, attached as an exhibit, offers an early view of how the company’s business performed in late 2025 ahead of its formal financial statements.

0001380106false00013801062026-01-132026-01-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 13, 2026

RAPID MICRO BIOSYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-40592			20-8121647
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification No.)
25 Hartwell Avenue, Lexington, MA						02421
(Address of principal executive offices)						(Zip Code)

978-349-3200

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbols

Name of each exchange on which registered

Class A Common Stock, $0.01 par value per share

RPID

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company þ

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On January 13, 2026, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue results and certain business highlights for the fourth quarter and full year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.

The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.						Description
99.1						Press Release of Rapid Micro Biosystems, Inc., dated January 13, 2026.
104						Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			RAPID MICRO BIOSYSTEMS, INC.
Date: January 13, 2026			By:			/s/ Sean Wirtjes
						Sean Wirtjes
						Chief Financial Officer

FAQ

What did Rapid Micro Biosystems (RPID) disclose in this 8-K?

Rapid Micro Biosystems disclosed that it issued a press release with preliminary unaudited revenue results and certain business highlights for the fourth quarter and full year ended December 31, 2025, which is furnished as Exhibit 99.1.

Which period does Rapid Micro Biosystems’ preliminary revenue update cover?

The preliminary revenue update for Rapid Micro Biosystems covers the fourth quarter and full year ended December 31, 2025.

Where can investors find the detailed preliminary results for RPID?

Investors can find the detailed preliminary results and business highlights in the press release attached as Exhibit 99.1 to the Form 8-K.

Are Rapid Micro Biosystems’ preliminary results in this 8-K considered filed financial statements?

No. The company states that the information furnished under Item 2.02, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

Who signed the Rapid Micro Biosystems 8-K regarding the preliminary results?

The Form 8-K was signed on behalf of Rapid Micro Biosystems, Inc. by Sean Wirtjes, Chief Financial Officer.

On which exchange is Rapid Micro Biosystems’ common stock traded?

Rapid Micro Biosystems’ Class A Common Stock is listed on The Nasdaq Capital Market under the trading symbol RPID.